Literature DB >> 12686511

CCK-58 is the only detectable endocrine form of cholecystokinin in rat.

Joseph R Reeve1, Gary M Green, Peter Chew, Viktor E Eysselein, David A Keire.   

Abstract

CCK-58 differs from CCK-8 in patterns of expression of pancreatic secretion of fluid and amylase and gallbladder contraction. These differences have physiological relevance only if CCK-58 release is stimulated by nutrients entering the intestine and if CCK-58 circulates in sizeable amounts. In this study, we report that when radiolabeled CCK-58 is added to rat blood and plasma is formed, there is extensive loss and degradation of the radioactive peptide. Therefore, a new method was developed to minimize loss and degradation of this label. This method recovered >85% of the label with no detectable degradation. Furthermore, the optimized method recovered all unlabeled exogenous cholecystokinin molecular forms in >80% yields. Blood from fasted rats and rats in which cholecystokinin release was stimulated by the trypsin inhibitor camostat contained only CCK-58 (3.5 +/- 0.5 and 17 +/- 1.5 fmol/ml, respectively). Because CCK-58 predominates in the blood, this molecular form should be used in studies on the physiology and pathophysiology of cholecystokinin.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12686511     DOI: 10.1152/ajpgi.00523.2002

Source DB:  PubMed          Journal:  Am J Physiol Gastrointest Liver Physiol        ISSN: 0193-1857            Impact factor:   4.052


  16 in total

1.  Electrophysiological evidence for distinct vagal pathways mediating CCK-evoked motor effects in the proximal versus distal stomach.

Authors:  Shiho Okano-Matsumoto; James A McRoberts; Yvette Taché; David W Adelson
Journal:  J Physiol       Date:  2010-11-15       Impact factor: 5.182

Review 2.  Gastrointestinal regulation of food intake.

Authors:  David E Cummings; Joost Overduin
Journal:  J Clin Invest       Date:  2007-01       Impact factor: 14.808

3.  Non-sulfated cholecystokinin-8 increases enteric and hindbrain Fos-like immunoreactivity in male Sprague Dawley rats.

Authors:  Amged I Dafalla; Thaer R Mhalhal; Kenneth Hiscocks; John Heath; Ayman I Sayegh
Journal:  Brain Res       Date:  2018-12-17       Impact factor: 3.252

4.  The RAPID method for blood processing yields new insight in plasma concentrations and molecular forms of circulating gut peptides.

Authors:  Andreas Stengel; David Keire; Miriam Goebel; Lena Evilevitch; Brian Wiggins; Yvette Taché; Joseph R Reeve
Journal:  Endocrinology       Date:  2009-10-09       Impact factor: 4.736

5.  Cholecystokinin-58 and cholecystokinin-8 exhibit similar actions on calcium signaling, zymogen secretion, and cell fate in murine pancreatic acinar cells.

Authors:  David N Criddle; David M Booth; Rajarshi Mukherjee; Euan McLaughlin; Gary M Green; Robert Sutton; Ole H Petersen; Joseph R Reeve
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2009-10-08       Impact factor: 4.052

Review 6.  Changes in the plasma membrane in metabolic disease: impact of the membrane environment on G protein-coupled receptor structure and function.

Authors:  Aditya J Desai; Laurence J Miller
Journal:  Br J Pharmacol       Date:  2017-08-03       Impact factor: 8.739

7.  Cholecystokinin-33, but not cholecystokinin-8 shows gastrointestinal site specificity in regulating feeding behaviors in male rats.

Authors:  Martha C Washington; Thaer R Mhalhal; Ayman I Sayegh
Journal:  Horm Behav       Date:  2016-08-04       Impact factor: 3.587

8.  CCK-58 elicits both satiety and satiation in rats while CCK-8 elicits only satiation.

Authors:  Joost Overduin; James Gibbs; David E Cummings; Joseph R Reeve
Journal:  Peptides       Date:  2014-01-24       Impact factor: 3.750

9.  Apolipoprotein A-IV enhances cholecystokinnin secretion.

Authors:  Jesse Zhan; Jonathan Weng; Brian G Hunt; W Sean Davidson; Min Liu; Chunmin C Lo
Journal:  Physiol Behav       Date:  2018-01-31

Review 10.  Overview of exocrine pancreatic pathobiology.

Authors:  Arun R Pandiri
Journal:  Toxicol Pathol       Date:  2013-11-03       Impact factor: 1.902

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.